Bibliographic record
Abstract
Dear Sir, The recent global outbreak of MPOX has underscored the urgent need for effective countermeasures, including vaccines. While significant progress has been made in vaccine development, several critical factors must be carefully considered to ensure their efficacy and equitable distribution. The currently existing MPOX Vaccines like, Jynneos (Bavarix), this FDA-approved vaccine is primarily used for smallpox prevention, but has also been shown to be effective against MPOX in animal studies.[1] It is a two-dose vaccine administered subcutaneously. Imvanix that is approved in the European Union and Canada for smallpox prevention. It is a single-dose vaccine administered intradermally.[2] Acambis is being developed by Bavarian Nordic and is currently undergoing clinical trials. It is a single-dose vaccine administered intradermally and Vaccinia Ankara (VACV-Ankara) is being developed by various research groups and is currently in preclinical development. It is a single-dose vaccine administered intramuscularly.[3] We do have some challenges and considerations though like efficacy and safety. While initial studies have shown promising results, it is imperative to conduct rigorous clinical trials to evaluate the long-term efficacy of MPOX vaccines. This includes assessing their durability over time and identifying potential waning immunity and safety profile. It is crucial to monitor for potential side effects and adverse reactions associated with MPOX vaccines. This includes short-term and long-term safety assessments. Also, the emergence of new MPOX variants could potentially compromise vaccine effectiveness. Ongoing research is essential to monitor viral evolution and adapt vaccine formulations as needed.[4] Production and distribution are also very crucial and scaling up vaccine production to meet global demand presents significant logistical challenges. Investing in manufacturing facilities, ensuring access to essential raw materials, and addressing potential bottlenecks in the supply chain are critical for ensuring adequate supply. Ensuring equitable distribution of MPOX vaccines, particularly to low- and middle-income countries, is essential for global health security. International collaboration, support for vaccine affordability, and addressing vaccine hesitancy are crucial to address this issue.[5] Public Health Measures are important for surveillance as they are essential for early detection and timely response to future MPOX outbreaks. This includes investing in diagnostic testing, contact tracing capabilities, and data analysis. Promoting education and awareness about MPOX transmission, risk reduction behaviors, and vaccination is crucial for preventing future outbreaks. This includes targeted messaging for at-risk populations, providing access to preventive resources, and addressing vaccine hesitancy. Ensuring adequate healthcare capacity to manage MPOX cases and provide supportive care is essential for mitigating the impact of outbreaks. This includes training healthcare workers, establishing isolation facilities, and ensuring access to essential medical supplies.[6] Ethical considerations should be considered in determining who should receive the vaccine first in the event of limited supply raises ethical questions. Factors such as age, occupation, health status, and risk of exposure should be considered when developing prioritization guidelines. Also, ensuring informed consent from vaccine recipients is essential for ethical vaccine administration. This involves providing clear information about the benefits, risks, and alternatives to vaccination.[7] CONCLUSION The development of Monkeypox virus (MPOX) vaccines represent a significant milestone in combating this infectious disease. However, it is essential to approach this endeavor with a balanced perspective, recognizing the challenges and limitations involved. By investing in research, production, and public health measures, we can effectively mitigate the threat of MPOX and protect global health. Data availability statement All the refrences are the source of data. Author contribution Conceptualization of the study by Isha Sangtani, writing original draft and editing done by Isha Sangtani and Shahzad Mirza. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.019 | 0.034 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.002 | 0.001 |
| Science and technology studies | 0.001 | 0.003 |
| Scholarly communication | 0.006 | 0.014 |
| Open science | 0.003 | 0.003 |
| Research integrity | 0.010 | 0.016 |
| Insufficient payload (model declined to judge) | 0.013 | 0.004 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".